CA
NZ
UK
AU
IND
US
● Nu-Med Plus, incorporated in 2011, describes itself as a developer and commercialiser of medical devices, with a focus on nitric oxide generation and delivery technology aimed at respiratory and cardiovascular care.
● NuVim built its identity years ago around functional, wellness-oriented beverages, nutrient-fortified, dairy-based drinks marketed for immune support and everyday nutrition.
Few 2025 debutants have swung as violently as Anbio Biotechnology (NASDAQ:NNNN). After listing barely eighteen months ago, the in-vitro diagnostics maker has travelled from a euphoric high above $50 to single digits, punctuated by repeatedVolatilityhalts.
Nutranomics, Inc. (OTC:NNRX) is a name from the nutritional-supplement corner of the micro-cap market, and its ticker still surfaces on penny-stock screens even though the company's public reporting has fallen silent. Quoted at essentially a hundredth of a cent with aMarket Valuein the tens …
NOHO (OTC:NOHO) is a reminder of how tangled the identity of a deep-penny OTC ticker can become. The symbol has long been associated with Novation Holdings Inc, but market-data providers now list the entity under a different corporate name, reflecting the kind of rebranding …
NeuroSense Therapeutics Ltd (NASDAQ:NRSN) occupies a corner of biotech where scientific promise collides with penny-stock economics. The Israel-based clinical-stage company is developing a combination therapy for amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease with few effective treatments, yet its Nasdaq-listed shares trade well …
A commercial launch, a product recall and a pending FDA decision are colliding at once for InspireMD, Inc (NASDAQ: NSPR), and the stock's latest dip reflects a company in the middle of a delicate transition. The Israel-based, Nasdaq-listed developer of embolic-protection stents is trying …
A rebrand, a new chief executive and a coveted FDA designation have combined to give NovaBridge Biosciences (NASDAQ:NBP) one of the more eventful years in immuno-oncology's small-cap ranks. The company that most investors knew until recently as I-Mab has reset its identity around a …
● The larger overhang is the proposed Scancell combination and the outcome of the company's strategic review.
A relatively new ticker on the Nasdaq, Niki BioSolutions, Inc (NASDAQ:NIKI) is drawing attention as a freshly rebranded clinical-stage biopharmaceutical company still establishing its market identity. The shares eased in early-September 2026 trading, a modest single-session slip that fits the pattern of a small, …
Please wait processing your request...